At that opening price, Moderna was valued at $7.32 billion, based on 332.9 million outstanding shares including over-allotment, making it the biggest biotech company to go public.
Moderna, largest biotech to go public, fails to impress in market debut
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain